Innovative Biodefense, Inc. v. VSP Technologies, Inc.

CourtDistrict Court, S.D. New York
DecidedMay 11, 2020
Docket1:12-cv-03710
StatusUnknown

This text of Innovative Biodefense, Inc. v. VSP Technologies, Inc. (Innovative Biodefense, Inc. v. VSP Technologies, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Innovative Biodefense, Inc. v. VSP Technologies, Inc., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

INNOVATIVE BIODEFENSE, INC.,

Petitioner,

– against – OPINION & ORDER 12 Civ. 3710 (ER) VSP TECHNOLOGIES, INC., SAN-MAR LABORATORIES, INC., and CARLO MICCERI,

Respondents.

Ramos, D.J.: This case concerns a fee dispute between Innovative Biodefense, Inc. (“IBD”)—the plaintiffs in the underlying litigation—and Hill, Farrer & Burrill LLP (“Hill Farrer”)—the law firm that represented IBD in that litigation through the summary judgment stage. After Hill Farrer withdrew from the litigation in September 2015, IBD and Hill Farrer resolved their fee dispute through arbitration, producing an award in Hill Farrer’s favor that was subsequently confirmed by the Superior Court of the State of California, County of Los Angeles. Hill Farrer now moves as a third-party (1) to enforce a charging lien, pursuant to New York Judiciary Law § 475, for the fixed amount of $356,635.94 against the settlement ultimately obtained by IBD in the underlying litigation; and (2) for a judgment in quantum meruit against IBD for the same amount plus post-judgment interest or, in the alternative, for a judgment enforcing the judgment of the California court. Because the Court finds both that Hill Farrer is not entitled to a charging lien, and also that the exercise of supplemental jurisdiction over their quantum meruit claim is inappropriate here, Hill Farrer’s principal motions are DENIED. However, Hill Farrer’s request in the alternative for a judgment enforcing the confirmation order of the California court is GRANTED. I. BACKGROUND A. The Parties IBD is a California corporation engaged in the development, manufacture, and sale of antimicrobial products, including skincare and cleansing products. Pl.’s Statement of Material Facts Supp. Mot. Summ. J. ¶ 1, Doc. 175 (hereinafter “Pl.’s 56.1”). VSP Technologies (“VSP”)

is a New York corporation that licenses and markets various technologies but does not itself manufacture or sell any product. Id. ¶ 2. San-Mar manufactures cosmetic products and is based in Elmsford, New York. Id. ¶ 3. Carlo Micceri served, at the relevant time, as VSP’s President, and was also involved in various capacities with San-Mar. Id. ¶¶ 4, 24. William A. Meyers (“Meyers”) and Neil D. Martin (“Martin”) are partners at Hill Farrer, the California-based law firm retained by IBD from the commencement of their action in May 2012 until September 14, 2015. William A. Meyers Decl. ¶¶ 1–6, Doc. 315 (hereinafter “Meyers Decl.”). Meyers has practiced law since 2009, and Martin has practiced law since 1980. Id. ¶ 6. Both Meyers and Martin were primarily responsible for representing IBD in the underlying

matter, and they billed IBD at an hourly rate of $340 and $510, respectively. Id. IBD agreed to the hourly rate of both attorneys upon retaining the firm, and Hill Farrer maintains that those rates were “less than the rates charged by comparable attorneys with the same experience . . . at comparable firms for work of this nature.” Id. B. The Underlying Litigation & Fee Dispute On May 9, 2012, IBD filed a complaint against VSP, San-Mar,1 and Micceri to resolve issues relating primarily to three patent sublicensing agreements. The complaint included eight causes of action against the various defendants for breach of contract, Compl. ¶¶ 28–44; tortious

1 IBD voluntarily dismissed San-Mar from the initial action on May 22, 2014. Docs. 96, 98. interference with prospective economic advantage, id. ¶¶ 45–54; tortious interference with contract, id. ¶¶ 55–65; fraudulent misrepresentation, id. ¶¶ 66–70; negligent misrepresentation, id. ¶¶ 71–74; two counts of fraudulent inducement, id. ¶¶ 75–84; and breach of an implied covenant of good faith and fair dealing, id. ¶¶ 85–92. On December 20, 2012, VSP and Micceri responded by asserting ten counterclaims

against IBD for breach of contract, Defs.’ Amended Answer, ¶¶ 97–101, Doc. 36; unjust enrichment, id. ¶¶ 102–106; unfair competition and false advertising, id. ¶¶ 107–17; dilution of trademark, id. ¶¶ 118–22; unfair business practices, id. ¶¶ 123–26; unfair competition, id. ¶¶ 127–34; false and fraudulent registration of a patent, id. ¶¶ 135–38; conspiracy to defraud, id. ¶¶ 139–43; breach of a confidentiality clause, id. ¶¶ 146–50; and reasonable attorneys’ fees, costs, and disbursement, id. ¶¶ 151–52. As the litigation proceeded, IBD missed several payments despite Hill Farrer’s continued practice of providing them with monthly invoices detailing the services provided, time spent, and corresponding charges. Hill Farrer’s Third-Party Mot. 2, Doc. 314 (hereinafter “HF’s Mot.”).

By August 5, 2015, IBD owed Hill Farrer $271,942.63. Id. As a result of IBD’s failure to make payments, Hill Farrer requested that IBD replace them as attorneys of record with new counsel. Id. IBD agreed but requested that Hill Farrer remain counsel of record through the completion of ongoing cross-motions for summary judgment, which had begun in March 2015. Meyer Decl., Ex. C at 2 (hereinafter the “Arbitral Award”).2 In September 2015, this Court granted Hill Farrer’s request for substitution. Consent Order Granting Substitution of Attorney, Doc. 205.

2 IBD’s motion was eventually granted in part and denied in part, while the defendants’ cross-motion was denied in its entirety. Innovative Biodefense, Inc. v. VSP Tech., Inc., 176 F. Supp. 3d 305 (S.D.N.Y. 2016). Pursuant to California practice, the parties engaged in arbitration to resolve the fee dispute. On October 21, 2016, IBD petitioned for arbitration, and on February 20, 2018, the panel issued an award ordering IBD to pay Hill Farrer $271,943, plus interest. Meyers Decl. ¶ 8. Hill Farrer then moved to confirm the award in the Superior Court of the State of California, County of Los Angeles, which, on June 28, 2018, entered a judgment against IBD for

$356,635.94, plus post-judgment interest. Id. ¶ 10.3 On July 3, 2018, IBD notified the Court that it had settled with VSP, Doc. 302, and on July 6, the parties stipulated to the dismissal of all claims and counterclaims, Doc. 308. Hill Farrer then filed this motion, seeking a charging lien on that settlement as well as a judgment in quantum meruit. The contents of the settlement agreement are confidential, but a copy has been provided to the Court for in camera review.4 II. LEGAL STANDARDS A. Charging Lien New York Judiciary Law § 475 allows attorneys to obtain a charging lien, enforceable

against the recovery of former clients, as a means of securing compensation for services that produced that recovery. In relevant part, the statute provides: [f]rom the commencement of an action, special or other proceeding in any court or before any state, municipal, or federal department, . . . the attorney who appears for a party has a lien upon his or her client’s cause of action, claim or counterclaim, which attaches to a verdict, report, determination, decision, award, settlement, judgment or final order in his or her client’s favor, and the proceeds thereof in whatever hands they may come . . . . The court upon petition of the client or attorney may determine and enforce the lien.

3 The parties had stipulated before the Superior Court as to the proper amount of the judgment. Meyers Decl. ¶ 9. 4 Although IBD claims to have provided Hill Farrer with a copy of the agreement for the purposes of this motion, Pl.’s Mem. Opp’n Mot. 2, Doc. 316, Hill Farrer represented in its papers that, at the time of execution, they had not been provided with a copy of the agreement, Meyers Decl. ¶ 12–13. N.Y. Jud. Law § 475. Courts have consistently held that charging liens under § 475 are “enforceable in federal courts in accordance with its interpretation by New York Courts.” Itar- Tass Russian News Agency v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Richard Ware Levitt, Esq. v. David H. Brooks
669 F.3d 100 (Second Circuit, 2012)
Indosuez v. Sopwith Holdings Corp.
772 N.E.2d 1112 (New York Court of Appeals, 2002)
ANTONMARCHI v. Consolidated Edison Co. of New York
678 F. Supp. 2d 235 (S.D. New York, 2010)
Stair v. Calhoun
722 F. Supp. 2d 258 (E.D. New York, 2010)
Liddle & Robinson, LLP v. Garrett
720 F. Supp. 2d 417 (S.D. New York, 2010)
Casper v. Lew Lieberbaum & Co., Inc.
182 F. Supp. 2d 342 (S.D. New York, 2002)
Oppenheim v. Pemberton
164 A.D.2d 430 (Appellate Division of the Supreme Court of New York, 1990)
Sequa Corp. v. GBJ Corp.
156 F.3d 136 (Second Circuit, 1998)
Innovative Biodefense, Inc. v. VSP Technologies, Inc.
176 F. Supp. 3d 305 (S.D. New York, 2016)
Achtman v. Kirby, McInerney & Squire, LLP
150 F. App'x 12 (Second Circuit, 2005)
Galvez v. Aspen Corp.
967 F. Supp. 2d 615 (E.D. New York, 2013)
Rosenman & Colin v. Richard
850 F.2d 57 (Second Circuit, 1988)
Cluett v. CPC Acquisition Co.
863 F.2d 251 (Second Circuit, 1988)

Cite This Page — Counsel Stack

Bluebook (online)
Innovative Biodefense, Inc. v. VSP Technologies, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/innovative-biodefense-inc-v-vsp-technologies-inc-nysd-2020.